Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 4/2018

01-04-2018 | Original Article

Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma

Authors: Aditya Bagrodia, Samuel Kaffenberger, Andrew Winer, Katie Murray, Michael Vacchio, Junting Zheng, Irina Ostrovnaya, Bernard H. Bochner, Guido Dalbagni, Eugene K. Cha, Jonathan A. Coleman

Published in: World Journal of Urology | Issue 4/2018

Login to get access

Abstract

Purpose

To evaluate the impact of timing of blood transfusion in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU).

Methods

Outcomes of consecutive patients with UTUC treated with RNU were analyzed. Clinicopathologic factors were compared using Fisher’s exact test or the Wilcoxon rank-sum test between patients who received any transfusion and no transfusion, and between patients receiving intraoperative transfusion only and patients receiving no transfusion. Cancer-specific and overall survival were estimated and multivariable analyses were performed to assess the impact of timing of transfusion on clinical outcomes.

Results

Among 402 patients included in this study, 71 (17.6%) patients received a transfusion at any point and 27 (6.7%) patients received an intraoperative blood transfusion. Transfusion at any time, patient comorbidity, high grade, advanced stage, positive surgical margins, low preoperative hemoglobin, longer operative duration, and increased blood loss were significantly associated with cancer-specific survival (DSS) on univariable analysis (HR 1.85, 95% CI 1.20–2.85, p < 0.005). In the multivariable analysis, transfusion at any point was not a prognostic factor (HR 1.00, 95% CI 0.60–1.68, p = 0.99). When examining intraoperatively transfusion only, transfusion was significantly associated with DSS (HR 1.91, 95% CI 1.01–3.59, p = 0.045) but no longer significant in multivariable analysis (HR 0.72, 95% CI 0.32–1.65, p = 0.440).

Conclusions

Our study indicates that the administration of blood transfusion either intraoperatively or postoperatively is not associated with clinical or oncological outcomes in patients with upper tract urothelial carcinoma when adjusted for other factors in multivariable analysis. Further study is required.
Appendix
Available only for authorised users
Literature
1.
Adibi M, Youssef R, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI et al (2012) Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol 19(12):1060–1066CrossRefPubMed
2.
Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115(6):1224–1233CrossRefPubMed
3.
Roupret M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR et al (2013) Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol 189(5):1662–1669CrossRefPubMed
4.
Seisen T, Krasnow RE, Bellmunt J, Roupret M, Leow JJ, Lipsitz SR et al (2017) Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol 35(8):852–860CrossRefPubMed
5.
Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Khalil D, Kapur P et al (2014) Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: results of a current series and a review of the literature. Urol Oncol 32(1):54e19-26CrossRef
6.
Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, Shariat SF et al (2011) Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 60(4):776–783CrossRefPubMed
7.
Rink M, Sharifi N, Fritsche HM, Aziz A, Miller F, Kluth LA et al (2014) Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 191(2):316–322CrossRefPubMed
8.
Rieken M, Schubert T, Xylinas E, Kluth L, Roupret M, Trinh QD et al (2014) Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol 40(12):1693–1699CrossRefPubMed
9.
Rink M, Soave A, Dahlem R, Aziz A, Al-Sayed F, Peine S et al (2016) Impact of perioperative allogenic blood transfusion on survival after radical nephroureterectomy for upper tract urothelial carcinoma. Clin Genitourin Cancer 14(1):96–104CrossRefPubMed
10.
Abel EJ, Linder BJ, Bauman TM, Bauer RM, Thompson RH, Thapa P et al (2014) Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol 66(6):1139–1147CrossRefPubMed
11.
Linder BJ, Frank I, Cheville JC, Tollefson MK, Thompson RH, Tarrell RF et al (2013) The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 63(5):839–845CrossRefPubMed
12.
Morgan TM, Barocas DA, Chang SS, Phillips SE, Salem S, Clark PE et al (2013) The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol 31(6):871–877CrossRefPubMed
13.
Vamvakas EC, Blajchman MA (2007) Transfusion-related immunomodulation (TRIM): an update. Blood Rev 21(6):327–348CrossRefPubMed
14.
Pesta M, Fichtl J, Kulda V, Topolcan O, Treska V (2013) Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Anticancer Res 33(5):2239–2243PubMed
15.
Vamvakas EC (1996) Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 36(2):175–186CrossRefPubMed
Metadata
Title
Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma
Authors
Aditya Bagrodia
Samuel Kaffenberger
Andrew Winer
Katie Murray
Michael Vacchio
Junting Zheng
Irina Ostrovnaya
Bernard H. Bochner
Guido Dalbagni
Eugene K. Cha
Jonathan A. Coleman
Publication date
01-04-2018
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 4/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2180-3

Other articles of this Issue 4/2018

World Journal of Urology 4/2018 Go to the issue

Editorial

Evolution of technologies in urology: full steam ahead?

Topic Paper

Prostatic artery embolization for benign prostatic obstruction: assessment of safety and efficacy

Original Article

Viability and biocompatibility of an adhesive system for intrarenal embedding and endoscopic removal of small residual fragments in minimally-invasive stone treatment in an in vivo pig model

Letter to the Editor

No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer

Topic Paper

Introducing new technology safely into urological practice

Original Article

Is the laser mightier than the sword? A comparative study for the urethrotomy